Recommendations for the Use of Radiotherapy in Nodal Lymphoma

Clinical Oncology

Volumn 25, Issue 1, 2013, Pages 49-58

  Hoskin, P J ^a   Diez P ^a   Williams, M ^b   Lucraft, H ^c   Bayne, M ^d  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d Poole Cancer Centre   (United Kingdom)

Author keywords

Hodgkin; Involved field; Involved node; Involved site; Lymphoma; Non Hodgkin; Radiotherapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INVOLVED FIELD RADIOTHERAPY; INVOLVED SITE RADIOTHERAPY; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MORBIDITY; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT POSITIONING; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; THREE DIMENSIONAL IMAGING; TREATMENT FAILURE; TUMOR VOLUME; WIDE FIELD RADIOTHERAPY;

COMBINED MODALITY THERAPY; HEALTH PLANNING GUIDELINES; HODGKIN DISEASE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871403940     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.07.011     Document Type: Article

References (47)

1. Featherstone C., Delaney G., Jacob S., Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I - lymphoma. Cancer 2005, 103(2):383-392.
2. International Commission on Radiation Units and Measurements Prescribing, recording and reporting photon beam therapy 1993, ICRU Report 50.
3. Gregoire V., Eisbruch A., Hamoir M., Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006, 79(1):15-20.
4. Taylor A., Rockall A.G., Powell M.E. An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol (R Coll Radiol) 2007, 19(7):542-550.
5. Lengele B., Hamoir M., Scalliet P., Gregoire V. Anatomical bases for the radiological delineation of lymph node areas. Major collecting trunks, head and neck. Radiother Oncol 2007, 85:146-155.
6. Lengele B., Nyssen-behets C., Scalliet P. Anatomical bases for the radiological delineation of lymph node areas. Upper limbs, chest and abdomen. Radiother Oncol 2007, 84:335-346.
7. Lengele B., Scalliet P. Anatomical bases for the radiological delineation of lymph node areas. Part III: pelvis and lower limbs. Radiother Oncol 2009, 92:22-33.
8. Martinez Monge A., Fernandes P.S., Gupta N., Gahbauer R. Cross sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Radiology 1999, 211:815-828.
9. Kaplan H.S. Hodgkin's disease 1980, Harvard University Press, Cambridge, MA, p. 375-407. 2nd ed.
10. Engert A., Schiller P., Josting A., et al. Involved field radiotherapy is equally effective and less toxic compared with extended field radiotherapy after four cycles of chemotherapy in patients with early stage unfavourable Hodgkin's lymphoma. Results of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003, 21:2003-3001.
11. Hoskin P.J., Smith P., Maughan T.S., et al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol 2005, 17:47-53.
12. Koh E.S., Tran T.H., Heydarian M., et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2:13.
13. Ferme C., Eqhbali H., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New Eng J Med 2008, 357:1916-1927.
14. Engert A., Franklin J., Eicht H.T., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007, 25(23):3495-3502.
15. Miller T.P., Dahlberg S., Cassady R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade non-Hodgkin's lymphoma. New Eng J Med 1998, 339:21-26.
16. Yahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002, 13(Suppl. 1):79-83.
17. Díez P., Hoskin P.J., Aird E.G. Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme. Br J Radiol 2007, 80(958):816-821.
18. Díez P., Hoskin P.J. Differences in volume definition between conventional and CT-based planning for involved-field radiotherapy of supra-diaphragmatic malignant lymphoma. Radiother Oncol 2006, 81(S1):S496. (abstract 1225).
19. Ruhl U., Albrecht M., Dieckmann K., et al. Response-adapted radiotherapy in the treatment of paediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001, 51(5):1209-1218.
20. Girinsky T., van der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79(3):270-277.
21. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 20:3484-3494.
22. Swerdlow A.J., Barber J.A., Hudson G.V., et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18:498-509.
23. van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487-497.
24. Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993, 85(1):25-31.
25. Travis L.B., Hill D.A., Dores G.M., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290(4):465-475.
26. De Bruin M.L., Sparidans J., van't Veer M.B., et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27(26):4239-4246.
27. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiation dose, chemotherapy and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
28. Milano M.T., Constine L.S., Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007, 17:131-140.
29. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
30. Donovan E.M., Ciurlionis L., Fairfoul J., et al. Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk (IMPORT High trial). Int J Radiat Oncol Biol Phys 2011, 79(4):1064-1072.
31. Marks L.B., Yorke E.D., Jackson A., et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl.):S10-S19.
32. Kaplan H.S. Evidence for a tumouricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966, 26:1221-1224.
33. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. New Eng J Med 1996, 334:745-751.
34. Loeffler M., Diehl V., Pfreundschuh M., et al. Dose-response of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease. J Clin Oncol 1997, 15:2275-2287.
35. Sieber M., Tesch H., Pfistner B., et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002, 20(2):476-484.
36. Engert A., Plutschow A., Eich H.T., et al. Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. New Engl J Med 2010, 363:640-652.
37. Eich H.T., Diehl V., Jorgen H., et al. Intensified chemotherapy and dose reduced involved field radiotherapy in patients with early unfavourable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010, 28:4199-4206.
38. Seydel H.G., Bloedorn F.G., Wizenberg M., Berk S. Time-dose relationships in radiation therapy of lymphosarcoma and giant follicle lymphoma. Radiology 1971, 98:411-418.
39. Cox J.D., Koehl R.H., Turner W.M., King F.M. Irradiation in the local control of malignant lymphoreticular tumors. Radiology 1974, 112:179-185.
40. Sutcliffe S.B., Gospodarowicz M., Bush R.S., et al. Role of radiation therapy in localised non-Hodgkins lymphoma. Radiother Oncol 1985, 4:211-223.
41. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non Hodgkin lymphoma. Radiother Oncol, in press.
42. Wu X., Li P., Zhao J., et al. Clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol 2008, 20:619-625.
43. Sawyer E.J., Timothy A.R. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol 1997, 42(1):49-51.
44. Haas R.L., Poortmans P., de Jong D., et al. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 2005, 41(12):1724-1730.
45. Murthy V., Thomas K., Foo K., et al. Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma Myeloma 2008, 8(4):241-245.
46. National Cancer Research Network Trials Portfolio. Available at: http://www.ncrn.org.uk.
47. Eich H.T., Staar S., Gossman A., et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004, 58:1121-1127.